This small study tested a brain stimulation treatment called repetitive transcranial magnetic stimulation (rTMS) in 30 ME/CFS patients. The treatment targeted specific areas of the brain involved in movement and decision-making. After treatment, most patients reported improvements in their ability to do daily activities, reduced dizziness when standing, better balance, and less pain.
Why It Matters
ME/CFS lacks approved treatments and many available options have limited evidence. This study explores a novel neuromodulatory approach targeting postulated CNS dysfunction in ME/CFS, potentially offering hope for patients with debilitating orthostatic intolerance and balance problems that severely restrict daily functioning.
Observed Findings
67% of patients (20/30) achieved ≥2-point improvement in performance status scores restricting activities of daily living.
83% of patients (10/12 with baseline orthostatic intolerance) completed the 10-minute standing test without symptoms after treatment.
88% of patients (15/17 with baseline disequilibrium) showed resolution of unstable standing with feet together and eyes closed.
70% of patients (7/10) with neuropathic pain or fibromyalgia reported symptom attenuation.
No adverse effects were reported in any of the 30 study participants.
Inferred Conclusions
rTMS appears effective in ameliorating multiple ME/CFS symptoms, with particularly strong effects on orthostatic intolerance and disequilibrium.
rTMS may improve functional capacity and ability to perform activities of daily living in ME/CFS patients.
rTMS is well-tolerated with no reported adverse effects in this patient population.
Remaining Questions
Does rTMS produce sustained symptom improvement beyond the study period, or do symptoms return over time?
How does rTMS compare to placebo or sham stimulation in a randomized controlled trial?
What This Study Does Not Prove
This study does not establish that rTMS is definitively effective for ME/CFS because it lacks a control group (placebo or sham rTMS), making placebo effects and natural symptom fluctuation impossible to rule out. The small sample size, single-arm design, and lack of long-term follow-up data mean results may not generalize to the broader ME/CFS population or demonstrate lasting benefit. Observational studies cannot prove causation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.